Enclomiphene vs Gonadorelin
A side-by-side research comparison of Enclomiphene and Gonadorelin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Enclomiphene | Gonadorelin |
|---|---|---|
| Full name | Enclomiphene Citrate | Gonadorelin (GnRH Analog) |
| Category | Hormone Replacement | Hormone Replacement |
| Status | Investigational drug | FDA Approved |
| Mechanism | Blocks estrogen receptors in the hypothalamus, reducing negative feedback and increasing GnRH pulsatility, which stimulates LH and FSH release for endogenous testosterone production. | Binds GnRH receptors on pituitary gonadotrophs to stimulate LH and FSH release, maintaining testicular/ovarian function and natural sex hormone production. |
| Molecular weight | 598.09 Da | 1182.39 Da |
| Half-life | 10-14 hours | ~10-40 minutes |
| Bioavailability | ~50% oral | ~90% subcutaneous |
| Typical dose | 12.5-25 mg | 100-500 mcg |
| Frequency | Daily | 2-3x per week or pulsatile |
| Route | Oral capsule | Subcutaneous injection |
Enclomiphene reported benefits
- Increased endogenous testosterone
- Preserved fertility
- Improved libido
- Enhanced energy and mood
- No testicular atrophy
Gonadorelin reported benefits
- Maintains natural hormone production
- Fertility preservation
- Testicular function support
- LH/FSH normalization
Related comparisons
Research and educational reference only. Not medical advice.